Genesis Group announced the completion of a $105 million cross-round financing

On December 23rd The Group announced the successful completion of a $105 million cross-round financing.
The current round of financing is led by China State-owned Enterprise Structural Adjustment Fund (CST), with Guiyuan Ventures, Qatar Investment Authority and a number of well-known institutions participating as new investors, and a number of existing shareholders, such as China Merchants Capital Transfer Investment And Acquisition Fund, Lilly Asia Fund, Teng Yue Fund, Sequoia Capital China Fund, etc., continue to participate.
Huaxing Capital acted as the lead financial adviser in the transaction and BOC International as the co-financial adviser.
Troen Group was merged in January 2019 by Maybos Bio and Yan'an Zishi Bio, and Dr. Zhao Yanning is the co-founder and executive chairman of Tseng Group, and Dr. Qian Xueming is the co-founder and CEO of Genesis Group.
the company's official website, it has built more than a dozen new drug projects of the product pipeline, covering oncology, orthopaedics, kidney disease and other diseases.
January 2020, The Company announced the successful completion of a $100 million B-plus round of financing.
, the company has so far financed more than $330 million.
2020 is a year of important milestones for the Genesis Group, according to a press release.
as multiple products enter the clinical stage, the Company has also made great achievements in advancing pipeline drug development.
The humanized Claudin 18.2 monoclonal antibody TST001 for solid tumors has gained rapid clinical advances in both China and the United States, and the second-generation immunotherapy PD-L1/TGF beta dual-specific molecule TST005 for solid tumors is also about to be declared IND in China and the United States.
: The Company completed a $105 million cross-round financing. Retrieved Dec 23, 2020, from Source: Medical Mission Hills